Finance

Lists
Q2 2026 earnings • released • EPS beat +44.22% • Revenue beat +7.71%
See results
NBIX:NASDAQ
Neurocrine Biosciences, Inc
$167.90
+0.66%
(+1.10) 1D
Aug 3, 3:31:14 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NBIX...
Open
$166.25
High
$170.88
Low
$164.01
Mkt. cap
16.93B
Avg. vol.
1.34M
Volume
859.24K
P/E ratio
24.60
52-wk high
$186.12
52-wk low
$122.14
EPS
$6.83
Beta
0.39
Shares outstanding
100.55M
No. of employees
2K
Open
$166.25
High
$170.88
Low
$164.01
Mkt. cap
16.93B
Avg. vol.
1.34M
Volume
859.24K
P/E ratio
24.60
52-wk high
$186.12
52-wk low
$122.14
EPS
$6.83
Beta
0.39
Shares outstanding
100.55M
No. of employees
2K
News stories
From sources across the web
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences, Inc
CEOKevin C. Gorman
Employees2K
Founded1992
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websiteneurocrine.com
Analyst ratings
Based on 26 analysts giving stock ratings to NBIX in the past 3 months
Strong buy
Buy
23
Hold
3
Sell
0
12-month forecast
Based on 26 Wall Street analysts offering 12 month price targets for NBIX in the last 3 months.
Highest
Current $167.90
$249.00 (+48.30%)
Average
$211.04 (+25.69%)
Lowest
$170.00 (+1.25%)
Analyst
Recommendation
Action
Price target
Projected
Date
Laura Chico
Wedbush
Buy
Maintained
$194.00
+15.5%
08/03/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Reiterated
$210.00
+25.1%
08/03/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$249.00
+48.3%
08/03/2026
Danielle Brill
Truist Financial
Buy
Reiterated
$213.00
+26.9%
08/03/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$215.00
+28.1%
07/31/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
07/31/2026
Jeffrey Walch
Bernstein
Buy
Maintained
$221.00
+31.6%
07/30/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
$200.00
+19.1%
07/31/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
-
-
07/30/2026
Ashwani Verma
UBS
Buy
Maintained
$231.00
+37.6%
07/31/2026
David Hoang
Deutsche Bank
Hold
Reiterated
$190.00
+13.2%
07/31/2026
Jay Olson
Oppenheimer
Buy
Maintained
$230.00
+37%
07/31/2026
Brian Abrahams
RBC Capital
Buy
Reiterated
$198.00
+17.9%
07/30/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$215.00
+28.1%
07/30/2026
Sean Laaman
Morgan Stanley
Hold
Maintained
$196.00
+16.7%
07/31/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
$225.00
+34%
07/31/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$215.00
+28.1%
07/31/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$210.00
+25.1%
07/31/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$222.00
+32.2%
07/31/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$214.00
+27.5%
07/30/2026
Ami Fadia
Needham
Buy
Reiterated
$204.00
+21.5%
07/31/2026
Phil Nadeau
TD Cowen
Buy
Reiterated
$220.00
+31%
07/31/2026
Unknown Analyst
Jefferies
Buy
Maintained
$200.00
+19.1%
07/30/2026
Evan Seigerman
BMO Capital
Hold
Maintained
$170.00
+1.3%
07/13/2026
Akash Tewari
Jefferies
Buy
Maintained
$200.00
+19.1%
06/30/2026
Corinne Johnson
Goldman Sachs
Buy
Initiated
$213.00
+26.9%
06/02/2026
Unknown Analyst
Bernstein
Buy
Initiated
$221.00
+31.6%
05/21/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$210.00
+25.1%
05/18/2026
Nevin Varghese
RBC Capital
Buy
Reiterated
$180.00
+7.2%
05/11/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$175.00
+4.2%
05/06/2026
Rudy Li
Wolfe Research
Buy
Reiterated
$160.00
-4.7%
04/06/2026
Daniel Giraldo
Bank of America Securities
Buy
Reiterated
$199.00
+18.5%
04/06/2026
Last report
Jul 30, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$2.85 / $1.98
+44.22%beat
Revenue / Est. (USD)
959.00M / 890.33M
+7.71%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
794.90M
805.50M
814.50M
959.00M
Cost of goods sold
264.00M
275.80M
310.00M
23.20M
Cost of revenue
264.00M
275.80M
310.00M
23.20M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
291.60M
302.50M
318.50M
383.10M
Operating expense
291.60M
302.50M
318.50M
782.80M
Total operating expenses
555.60M
578.30M
628.50M
806.00M
Operating income
239.30M
227.20M
186.00M
217.80M
Other non operating income
-
-
-
-
EBT including unusual items
291.80M
239.40M
246.80M
162.20M
EBT excluding unusual items
261.50M
253.00M
214.10M
162.50M
Income tax expense
82.30M
85.70M
48.90M
17.80M
Effective tax rate
28.20%
35.80%
19.81%
10.97%
Other operating expenses
-
-
-
-
Net income
209.50M
153.70M
197.90M
144.40M
Net profit margin
26.36%
19.08%
24.30%
15.06%
Earnings per share
2.17
1.88
1.94
2.85
Interest and investment income
22.20M
25.80M
28.10M
17.50M
Interest expense
-
-
-
-2.90M
Net interest expenses
22.20M
25.80M
28.10M
9.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
247.00M
234.70M
193.30M
225.10M
Gain or loss from assets sale
-
-
-28.60M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps